title: Prevention of thrombus formation on biomaterials exposed to blood using different antiplatelet drugs: experimental study in dogs.
abstract: An ex vivo shunt, established in dogs between both femoral arteries and right atrium, has been used to quantify the platelet deposition on six prosthetic materials used in the construction of cardiovascular prostheses: highly porous knitted Dacron (intervascular HP 800, 1400 mL/cm2/min/120 mm Hg), low-porosity woven Dacron (intervascular LP 200, 200 mL/cm2/min/120 mm Hg), double velour knitted Dacron, Avcothane 51 elastomere, and the mesothelial and epipericardial surfaces of bovine pericardium. In the search for a method to prevent platelet thrombi formation on these materials, we studied four groups of dogs: group 1 (control), group 2 (5 mg/kg body weight (BW)/day acetylsalicylic acid), group 3 (20 mg/kg BW/day acetylsalicylic acid), and group 4 (5 mg/kg BW/day acetylsalicylic acid plus 5 mg/kg BW/day dipyridamole). Platelets were labeled with 111In-oxine. The least thrombogenic material was Avcothane 51 elastomere. The only effective treatment for reduction of platelet deposition on the six materials was 5 mg/kg BW/day of acetylsalicylic acid. The dose used in group 3 only decreased the deposition of platelets on three of the six materials studied. The treatment employed in group 4 did not significantly reduce the deposition of platelets on any of the materials when compared with the control group.
authors.affiliation: Hospital Puerta de Hierro, Madrid, Spain.
authors.forename: M C
authors.initials: MC
authors.lastname: Escudero
authors.forename: L
authors.initials: L
authors.lastname: Alvarez
authors.forename: J
authors.initials: J
authors.lastname: de Haro
authors.forename: I
authors.initials: I
authors.lastname: Millán
authors.forename: E
authors.initials: E
authors.lastname: Jorge
authors.forename: J L
authors.initials: JL
authors.lastname: Castillo-Olivares
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001672:Biocompatible Materials / Q000009:adverse effects; D001769:Blood; D004176:Dipyridamole / Q000494:pharmacology; D004285:Dogs; D007205:Indium Radioisotopes; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D010976:Platelet Count; D019736:Prostheses and Implants; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D001672:Biocompatible Materials; D007205:Indium Radioisotopes; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin